MIRM
Mirum Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$91.83
−7.07%Sep 8, 2026, 12:36 UTC
Joanne Quan will step down as Chief Medical Officer of Mirum Pharmaceuticals, Inc., effective September 2, 2026, with Rob Myers appointed as her successor effective September 21, 2026.
Aug 25, 2026, 08:09 UTC
BlackRock Inc. disclosed a new stake of 4,390,063 shares in Mirum Pharmaceuticals, Inc., valued at approximately $513.95 million, representing about 7.20% ownership, in a recent SEC filing.
Source:Aug 5, 2026, 00:00 UTC
Mirum Pharmaceuticals reported Q2 2026 financial results with total revenue of $176.2 million, including Livmarli net product sales of $128.7 million and bile acid medicines net product sales of $47.5 million, and a net loss of $67.2 million.
Jun 14, 2026, 20:35 UTC
The U.S. FDA accepted the New Drug Application for zilurgisertib in fibrodysplasia ossificans progressiva under Priority Review.
Jun 14, 2026, 20:35 UTC
Mirum Pharmaceuticals and Incyte announced positive pivotal Phase 2 results from the PROGRESS study of zilurgisertib in fibrodysplasia ossificans progressiva.
Source: